C-Rad Valuation Multiples

C-Rad Overview

About C-Rad

C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.

Founded

2004

HQ

Employees

99

Website

c-rad.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $51M

EBITDA: $8M

EV

$81M

Valuation Multiples

Multiples.vc

Start free trial

C-Rad Financials

C-Rad reported last 12-month revenue of $51M and EBITDA of $8M.

In the same LTM period, C-Rad generated $35M in gross profit, $8M in EBITDA, and $3M in net income.

C-Rad P&L

In the most recent fiscal year, C-Rad reported revenue of $50M and EBITDA of $6M.

C-Rad expects next 12-month revenue of XXX and NTM EBITDA of XXX

C-Rad Stock Performance

C-Rad has current market cap of $99M, and enterprise value of $81M.

C-Rad's stock price is $3.00.

C-Rad Valuation Multiples

C-Rad trades at 1.6x EV/Revenue multiple, and 10.6x EV/EBITDA.

C-Rad Financial Valuation Multiples

As of April 20, 2026, C-Rad has market cap of $99M and EV of $81M.

Equity research analysts estimate C-Rad's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

C-Rad has a P/E ratio of 31.0x.

C-Rad Margins & Growth Rates

C-Rad's revenue in the last 12 month grew by 10%.

C-Rad's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

C-Rad's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

C-Rad's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

C-Rad Public Comps

See public comps and valuation multiples for other Medical Devices comps.

C-Rad M&A Activity

C-Rad acquired XXX companies to date.

Last acquisition by C-Rad was on XXXXXXXX, XXXXX. C-Rad acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

C-Rad Investment Activity

C-Rad invested in XXX companies to date.

C-Rad made its latest investment on XXXXXXXX, XXXXX. C-Rad invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).